![]() ![]() The regenerative properties of stem cell-based treatment provide an attractive approach for long-term seizure control, particularly in drug-resistant epilepsy. Stem cell therapy is potentially a promising novel therapeutic strategy for epilepsy. Prolonged seizures or uncontrolled chronic seizures would give rise to neuronal damage or death, astrocyte activation, reactive oxygen species production, and mitochondrial dysfunction. Over 20–30% of epilepsy patients fail to achieve seizure control or soon become resistant to currently available therapies. Overall, the outcomes of this patient suggest a potential cell therapy for autoimmune encephalitis and its neurological consequences.Įpilepsy is a common disabling chronic neurological disorder characterized by an enduring propensity for the generation of seizures that result from abnormal hypersynchronous firing of neurons in the brain. Cerebral atrophy was reduced on brain magnetic resonance imaging (MRI). Control of urinary and bowel functions was completely recovered. At the last visit, she was capable of walking, writing, and counting numbers. Her cognition and motor functions improved progressively after three UC-MSC infusions. Before cell therapy, she was in a permanent vegetative state with diffuse cerebral atrophy. At baseline and after each UC-MSC administration, the patient was examined by the German Coma Recovery Scale (CRS), the Gross Motor Function Classification System (GMFCS), the Gross Motor Function Measure–88 (GMFM-88), the Manual Ability Classification System (MACS), the Modified Ashworth Scale, and the Denver II test. The patient received three intrathecal infusions of xeno- and serum-free cultured UC-MSCs at a dose of 10 ⁶ cells/kg. Despite intensive therapy, the patient’s condition worsened so that allogenic UC-MSC therapy was contemplated. ![]() A 5-year-old girl was diagnosed with NMDA receptor encephalitis and treated with immunosuppressive medicaments and intravenous immunoglobulin (IVIG). This study reports the first patient with severe neurologic sequelae after NMDA receptor encephalitis treated with allogeneic umbilical cord–derived mesenchymal stem/stromal cells (UC-MSCs). Stem cell treatment in epileptic patients and its interaction with ASMs.Īnti- N-methyl-d-aspartate (NMDA) receptor encephalitis is caused by altered patient immune reactions. Further research is required to understand the potential of Overall, the characteristics of MSCs to be genetically engineered, in order to replace dysfunctional elements with the aim of restoring normal tissue functioning, suggested that these cells could be good candidates for the treatment of epilepsy refractory to ASMs. Neuroinflammation in different neurological disorders, including epilepsy. In this regard, their ability to differentiate into various cell types, reach damaged tissues and produce and release biologically active molecules with immunomodulatory/antiinflammatory and regenerative properties make them a high-potential therapeutic tool to address In addition, we discuss more recent findings on mesenchymal stem cells (MSCs) in pre-clinical and clinical investigations. That ASMs produce significant effects on the differentiation and determination of stem cell fate. Here, we review the effects of ASMs on stem cell treatment when they could be, as expected, co-administered. Although the vast majority of patients may be successfully managed with currently used antiseizure medication (ASM), the search for alternative therapies is still necessary due to pharmacoresistance in about 30% of patients with epilepsy. Epilepsy is a life-threatening neurological disease that affects approximately 70 million people worldwide. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |